Recent developments highlight Scienture Holdings' progress in product commercialization, funding, patent awards, and regulatory compliance, alongside challenges with Nasdaq listing.

• Scienture Holdings faces Nasdaq compliance challenges as of March 2026 [N1].
• The company's stock price increased 31% following Group Purchasing Organization (GPO) agreements for REZENOPY naloxone spray in March 2026 [N2].
• Maxim Group initiated coverage of Scienture Holdings with a buy recommendation in February 2026 [N3].
• REZENOPY was awarded an Orange Book-listable patent valid until 2041 in January 2026 [N4].
• Scienture prepared for the launch of REZENOPY, its highest-strength naloxone nasal spray, in December 2025 [N5].
• The company secured $3.9 million through a registered direct stock offering in August 2025 [N6].
• Scienture Holdings secured $3 million bridge funding in July 2025 to support product launches and pipeline development [N7].
• The company regained compliance with Nasdaq listing requirements in July 2025 [N8].

Scienture Holdings has successfully launched Arbli™, the first FDA-approved oral liquid losartan formulation, and secured exclusive U.S. rights to REZENOPY™, a naloxone nasal spray with patent protection through 2041. The company is advancing a pipeline of novel CNS and CVS product candidates, including SCN-104 and SCN-106, with ongoing clinical and regulatory progress. Recent funding rounds and regained Nasdaq compliance support operational stability. Positive pharmacokinetic and safety data for pipeline products and strategic partnerships may enable expansion of the marketed portfolio and revenue growth [S1][N2][N3].

Scienture Holdings faces significant risks including ongoing Nasdaq compliance challenges and a net loss of $41.5 million in fiscal 2025, indicating financial strain. The company is dependent on regulatory approvals and timely commercialization of its products, which may be impacted by FDA delays, government shutdowns, and workforce reductions. The early-stage nature of its pipeline products entails clinical and development risks. Market acceptance of new formulations and competition in specialty pharmaceuticals may limit commercial success. Liquidity constraints and the need for additional capital raise execution pose further risks [S1][S2][N1].

Scienture Holdings' moat is supported by its FDA-approved proprietary products, including Arbli™, the first FDA-approved oral liquid formulation of losartan potassium, and REZENOPY™, a naloxone nasal spray with an Orange Book-listable patent valid until 2041. The exclusivity and patent protection for these products provide barriers to entry. Additionally, the company's focus on specialty pharmaceuticals for CVS and CNS diseases, combined with its development pipeline and regulatory approvals, contribute to its competitive positioning. The company's ability to secure exclusive commercialization rights and develop novel formulations enhances its market differentiation [S1][N4].

• Regulatory Risks: Delays or failures in FDA approvals due to government shutdowns, workforce reductions, or policy changes could materially impact product commercialization and revenue generation [S2].
• Financial Risks: The company reported a net loss of $41.5 million in fiscal 2025 and relies on capital raises and funding to support operations and pipeline development [S1][N6][N7].
• Nasdaq Compliance Risks: Ongoing challenges with Nasdaq listing compliance may affect the company's ability to maintain its listing and access capital markets [N1].
• Pipeline Development Risks: Clinical development of pipeline products such as SCN-104 and SCN-106 involves inherent risks of delays, failures, or adverse results that could affect future prospects [S1].
• Market Acceptance Risks: New product formulations and acquisitions require successful market adoption and competition with existing therapies may limit commercial success [S1].

• Scienture Holdings, Inc. operates through its wholly owned subsidiary Scienture LLC, a specialty pharmaceutical company focused on cardiovascular (CVS) and central nervous system (CNS) diseases [S1].
• Scienture LLC launched its first commercial product, Arbli™ (SCN-102), an FDA-approved oral liquid formulation of losartan potassium for hypertension and related indications, in Q3 2025 [S1].
• Arbli™ is the first and only FDA-approved oral liquid formulation of losartan on the market [S1].
• Scienture LLC acquired the commercial-ready product REZENOPY™ (SCN-110), a naloxone HCl nasal spray (10mg/0.11mL), and holds exclusive U.S. commercialization rights [S1].
• REZENOPY™ has been awarded an Orange Book-listable patent valid until 2041 [N4].
• Pharmacokinetic studies support REZENOPY™'s comparable exposure and safety relative to reference naloxone treatments [S1].
• Scienture LLC is developing additional product candidates including SCN-104, a multi-dose dihydroergotamine mesylate injection pen for migraine and cluster headaches, and SCN-106, a potential biosimilar thrombolytic agent [S1].
• The company has conducted preclinical and pharmacokinetic studies for SCN-104 and plans to initiate a Phase 1 study in 2026 pending FDA clearance [S1].
• Scienture Holdings secured $3.9 million through a registered direct stock offering in August 2025 and $3 million bridge funding in July 2025 to support product launches and pipeline development [N6][N7].
• The company regained compliance with Nasdaq listing requirements in July 2025 [N8].
• Leadership transition occurred in May 2025 with Suren Ajjarapu stepping down as CEO and Chairman [N/A].
• Scienture Holdings terminated an equity line of credit in June 2025 to focus on launching FDA-approved Arbli™ [N/A].
• The FDA approved Arbli™ in March 2025, with commercial launch in Q3 2025 [S1].
• Scienture Holdings faces ongoing Nasdaq compliance challenges as of March 2026 [N1].
• Liquidity ratios as of December 31, 2025, include a current ratio of 2.89 and a cash ratio of 2.44, with cash and equivalents of approximately $6.66 million [S1].
• The company reported a net loss of approximately $41.5 million and basic and diluted EPS of -2.7 for fiscal year 2025 [S1].
• The company is subject to risks related to FDA and SEC regulatory delays, including impacts from government shutdowns and workforce reductions [S2].